|
Index of reports
> Cases with Breast Cancer Metastatic ()
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Estrace (Estradiol Vaginal) where reactions include breast cancer metastatic. The selected reports were submitted to the FDA during the sample period of about a year.
Possible Estrace side effects in female
Reported by a lawyer from United States on 2012-07-05
Patient: female, weighing 52.0 kg (114.4 pounds)
Reactions: Breast Cancer Metastatic
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Activella
Dosage: 1mg/0.5mg
Indication: Hormone Replacement Therapy
Start date: 2003-01-01
End date: 2003-08-01
Cycrin
Dosage: 2.5 mg unk
Indication: Hormone Replacement Therapy
Start date: 1995-02-01
End date: 1997-02-01
Estrace
Dosage: 0.1mg/gm
Indication: Hormone Replacement Therapy
Start date: 2002-03-01
Medroxyprogesterone
Dosage: unk
Administration route: Oral
Indication: Hormone Replacement Therapy
Start date: 1995-01-01
End date: 2003-09-01
Premarin
Dosage: 0.625 mg, unk
Administration route: Oral
Indication: Hormone Replacement Therapy
Start date: 1995-02-01
End date: 1997-02-01
Prempro
Dosage: 0.625/2.5mg
Administration route: Oral
Indication: Hormone Replacement Therapy
Start date: 1997-02-01
End date: 2003-01-01
Prempro
Dosage: 0.45mg/1.5mg
Start date: 2003-08-01
End date: 2003-10-01
Provera
Dosage: 2.5 mg, unk
Administration route: Oral
Indication: Hormone Replacement Therapy
Start date: 1995-04-01
End date: 1996-06-01
Other drugs received by patient: Fosamax
|
